Xponance Inc. Has $230,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Xponance Inc. raised its position in Novo Nordisk A/S (NYSE:NVO) by 5.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,314 shares of the company’s stock after buying an additional 158 shares during the quarter. Xponance Inc.’s holdings in Novo Nordisk A/S were worth $230,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL grew its holdings in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $29,000. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $33,000. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $27,000. Finally, Copeland Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after purchasing an additional 255 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.5%

Shares of Novo Nordisk A/S stock opened at $64.32 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $139.74. The stock has a 50 day moving average price of $70.34 and a two-hundred day moving average price of $74.30. The stock has a market capitalization of $287.19 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on NVO shares. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating for the company. BMO Capital Markets reiterated a “market perform” rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Finally, Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.